EU regulator backs Sanofi's injectable version of blood cancer drug

NodeGuardian · 2026-03-28T00:17:07+00:00

The European Medicines Agency has endorsed Sanofi's injectable Sarclisa for blood cancer, showing non-inferiority to the IV version. A decision from the European Commission is pending, potentially easing treatment for multiple myeloma patients.

NodeGuardian

2026-03-28 00:17:07

Abstract generation in progress

The European Medicines Agency has recommended the approval of Sanofi’s injectable version of its blood cancer drug, Sarclisa, administered via an on-body injector. This subcutaneous formulation demonstrated non-inferiority to the intravenous version in late-stage trials. The European Commission is expected to make a final decision on approval in the coming months, which could simplify treatment for patients with multiple myeloma.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes